menu
    • menu
    [{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KQB168","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kumquat Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kumquat Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KQB198","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kumquat Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kumquat Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KQB198","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kumquat Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kumquat Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KQB365","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kumquat Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kumquat Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Kumquat Biosciences","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.3300000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Kumquat Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Kumquat Biosciences","amount2":2.0699999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":2.0699999999999998,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Kumquat Biosciences \/ Eli Lilly"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"KRAS G12D","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kumquat Biosciences","amount2":1.3,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Bayer AG","highestDevelopmentStatusID":"5","companyTruncated":"Kumquat Biosciences \/ Bayer AG"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KQB548","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I","graph3":"Kumquat Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kumquat Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kumquat Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Kumquat Biosciences

    Menu

    Kumquat Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KQB548

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

                            Details : KQB548 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 06, 2025

                            Lead Product(s) : KQB548

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Bayer AG

                            Deal Size : $1,300.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bayer and Kumquat Biosciences Enter Global License and Collaboration in Precision Oncology

                            Details : The collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancreatic, colorectal and lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 12, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Bayer AG

                            Deal Size : $1,300.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KQB168

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            KQB168 Safety and Efficacy Monotherapy/Combo In Advanced Solid Tumors

                            Details : KQB168 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 29, 2025

                            Lead Product(s) : KQB168

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KQB365

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants Wit...

                            Details : KQB365 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 06, 2024

                            Lead Product(s) : KQB365

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KQB198

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants Wit...

                            Details : KQB198 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 17, 2024

                            Lead Product(s) : KQB198

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KQB198

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants Wit...

                            Details : KQB198 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 18, 2024

                            Lead Product(s) : KQB198

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $1,330.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Kumquat Biosciences Partners with Takeda On Oral Immuno-Oncology Drug

                            Details : Kumquat granted Takeda a global license to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono- or combination-therapy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $130.0 million

                            April 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $1,330.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Kumquat Biosciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $2,070.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lilly and Kumquat Biosciences Discover and Develop Novel Small Molecules

                            Details : Kumquat will utilize its small molecule immuno-oncology platform to discover novel clinical candidates and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldwide, excluding Greater China...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $70.0 million

                            July 29, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Eli Lilly

                            Deal Size : $2,070.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth